Ï Î.É. åîïìïëïãåßôáé...

Boy ¸ãéíá êáé åãþ ðñüóöáôá ìÝëïò ôçò ïéêïãÝíåéáò ôùí HIV+ áôüìùí.

Äåí îÝñù áêüìá áí íôñÝðïìáé ãé´áõôü ðïõ åßìáé, îÝñù üìùò Ýíá ðñÜãìá: üôé åßìáé Üíèñùðïò êé üðùò üëïé ìáò, êÜíïõìå ëÜèç.
Ç åéñùíßá åßíáé üôé êÜðïõ ìÝóá ìïõ ðÞãáéíá ãõñåýïíôáò.

Åßìáé 29 ÷ñïíþí êáé ôá ôåëåõôáßá 4 ÷ñüíéá åîåôáæüìïõí ãéá HIV 2 öïñÝò ôï ÷ñüíï.
Åß÷á 4 åðáöÝò ÷ùñßò êáðåëÜêé (á÷ áõôü ôï êáðåëÜêé ðïõ óôåñåß ôçí áðüëõôç åðáöÞ!) ìå áãíþóôïõò áðü ôï éíôåñíåô êáé Þôáí áíáìåíüìåíï.

Ç áíáêïßíùóç ôùí áðïôåëåóìÜôùí Þôáí êáôÜ êÜðïéï ôñüðï ç ëýôñùóÞ ìïõ.

Ãéáôß íá ôï êÜíù áõôü óôïí åáõôü ìïõ; Ãéáôß íá Ý÷ù åðáöÝò ÷ùñßò ðñïóôáóßá;
¸ðñåðå íá ðÜèù ãéá íá áñ÷ßóù íá áãáðþ ôç æùÞ.
Äåí îÝñù áí áãáðþ ôïí åáõôü ìïõ áêüìá, áëëÜ óßãïõñá Ý÷ù Ýíáí Üíèñùðï ìáæß ìïõ ðïõ èá ìå óôçñßæåé óôçí áíáãÝííçóÞ ìïõ.
Ãéáôß íáé, æþíôáò ìå ôïí HIV ìáèáßíåéò íá åêôéìÜò êáé íá óÝâåóáé ôç æùÞ ôïõ Üëëïõ.

Ç óýíôñïöüò ìïõ (åßìáóôå ìáæß 8 ÷ñüíéá), Þîåñå ãéá ôéò åðéêßíäõíåò óõìðåñéöïñÝò ìïõ.
ÐÜíôá ìå ðñïåéäïðïéïýóå, ü÷é üôé åãþ åß÷á Üãíïéá ôïõ êéíäýíïõ áëëÜ ðÜíôá ìïõ Ýëåãå üôé èá ôçí ðáôÞóù êáé íá ðñïóÝ÷ù.

Äõóôõ÷þò åß÷á õðåñåêôéìÞóåé ôï íÝï ìïõ "óõãêÜôïéêï" êé áõôü ãéáôß äåí ðßóôåõá üôé èá æçôïýóå Üóõëï óôï äéêü ìïõ óþìá.
Ãéáôß üìùò;

Ðñéí åíÜìéóç ÷ñüíï äþñï Èåïý ÷ôýðçóå ôçí ðüñôá ìáò êáé åìåßò, åðéêáëïýìåíïé ôçí ïéêïíïìéêÞ êñßóç, ôï åðéóôñÝøáìå.
¢ëëïé êÜíïõí áãþíá ãéá íá öÝñïõí óôç æùÞ Ýíá ðáéäß êáé åìåßò åßìáóôáí á÷Üñéóôïé.

Íïìßæù óôç æùÞ üëá ãéá êÜðïéï ëüãï ãßíïíôáé.
Äåí Ýâáæá ðñïöõëáêôéêü, ðÜñå ôþñá íá Ý÷åéò Ýíáí (õ)éü.
Äåí êñÜôçóåò ôï ðáéäß ðïõ Þñèå áíáðÜíôå÷á óôç æùÞ óïõ.
Ôþñá ìðåò óôç äéáäéêáóßá ôçò åíäå÷üìåíçò ôå÷íçôÞò ãïíéìïðïßçóçò êáé óå Ýíáí áôÝñìïíï áãþíá ãéá íá ðáñáìåßíåé ïñïáñíçôéêÞ Þ óýíôñïöüò óïõ.
ÔÝóðá åßìáé áêüìá óôçí áñ÷Þ êáé ðéóôåýù áõôÜ ðïõ ëÝù íá óõíå÷ßóù íá ôá êÜíù ðñÜîç äåß÷íïíôáò óåâáóìü óôç æùÞ.

Íá êëåßóù ìå Ýíá ôåôñÜóôé÷ï ðïõ ôï óêÝöôçêá ôçí åðïìÝíç ôçò áíáêïßíùóçò ôçò ïñïèåôéêüôçôÜò ìïõ:
- Ôï áßìá ìïõ åßíáé äçëçôçñéáóìÝíï
- Ìá ç áãÜðç ìïõ áãíÞ
- Ãéá óÝíá ðñéãêßðéóóá ôçò êáñäéÜò ìïõ
- Èá äéíá üëç ìïõ ôçí æùÞ

Îáíèüò Éððüôçò




... 'Aëëåò éóôïñßåò ...



Lancet

Ðñüóöáôåò äçìïóéåýóåéò óôï ðåñéïäéêü The Lancet HIV

Optimised second-line regimens in the public health approach

Globally, most people receive antiretroviral therapy (ART) in programmes that follow the WHO-recommended public health approach, using a small number of standard regimens and simplified monitoring.1 A single standard regimen—dolutegravir (an integrase strand transfer inhibitor [INSTI]) with tenofovir disoproxil fumarate and lamivudine (both nucleoside reverse transcriptase inhibitors, [NRTIs])—is currently taken by the large majority of people on ART in these programmes, including those on second-line therapy (following previous failure of a non-NRTI regimen).

Prioritising HIV drug resistance testing according to risk

Tenofovir–lamivudine–dolutegravir (TLD) is recommended as an initial treatment regimen and a preferred optimised regimen for people living with HIV without a history of previous viral non-suppression, referred to as TLD in first-line therapy (TLD-1). For people living with HIV with persistent viral non-suppression, TLD largely replaced protease inhibitor-based regimens following efavirenz-based initial regimens, referred to as TLD in second-line therapy (TLD-2), as it is at least as effective, better tolerated, and more affordable.

Ending paediatric AIDS: time to close implementation gaps

WHO's global health sector strategies on HIV, conceived to guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS by 2030, target a reduction in the number of children aged 0–14 years newly infected with HIV from 150 000 in 2022 to 20 000 in 2025 and 15 000 in 2030.1 To track progress toward these targets, accurate estimations of the number of annual infections in children in each country is crucial. However, in many low-income and middle-income countries, where the burden of paediatric HIV is the highest, children are not systematically tested for HIV in programmes for the prevention of vertical transmission (PVT).

About us

Óôï hivaids.gr, öéëïîåíïýìå áöéëïêåñäþò ôï "Ðñüãñáììá Óõíåñãáóßáò" ÌïíÜäùí Ëïéìþîåùí ãéá ôçí áíÜðôõîç äéáäéêôõáêÞò ôñÜðåæáò êëéíéêþí ðáñáìÝôñùí. Ôï Ðñüãñáììá äçìéïõñãÞèçêå áðü Ýíáí ãéáôñü åéäéêü óôçí HIV ëïßìùîç ìå ôç óõììåôï÷Þ ôùí ÌïíÜäùí: Ðåñéóóüôåñá

% Áíáðçñßá êáé HIV

ÍÝïò êáíïíéóìüò

Åíéáßïò Ðßíáêáò Ðñïóäéïñéóìïý Ðïóïóôïý Áíáðçñßáò

Çìåñïëüãéï

@ Äéáýãåéá

ÄéáýãåéáÄé@ýãåéá

äéáöÜíåéá óôï êñÜôïò

ÄéáäéêôõáêÝò áíáñôÞóåéò äéïéêçôéêþí áðïöÜóåùí ãéá ôï HIV/AIDS

¸ñåõíá

Óáò Ý÷åé óðÜóåé ðïôÝ ôï ðñïöõëáêôéêü êáôÜ ôç äéÜñêåéá ìéáò åñùôéêÞò åðáöÞò;
Íáé
¼÷é
Äåí ÷ñçóéìïðïéþ

Åðéêïéíùíßá

Newsletter

Áíáêïéíþóåéò

×ñÞóéìåò ðëçñïöïñßåò